唑来膦酸注射液治疗高龄老年性骨质疏松的药物不良反应发生情况研究

发布时间：2018-05-11 12:08

本文选题：骨质疏松 + 唑来膦酸　；参考：《中国全科医学》2017年28期

【摘要】：目的了解唑来膦酸注射液治疗高龄老年性骨质疏松的药物不良反应发生情况,并探讨高龄与药物不良反应发生的相关性。方法选取2011年3月—2016年7月在扬州市第一人民医院就诊的老年性骨质疏松患者45例,根据年龄分为老年组(年龄60~74岁,n=26)和高龄组(年龄75~88岁,n=19)。收集并比较两组患者的基线资料和药物不良反应发生情况,采用偏相关分析探讨高龄与药物不良反应发生的相关性。结果两组患者性别、BMI、骨钙素、钙离子、磷离子、碱性磷酸酶(ALP)、甲状旁腺激素(PTH)、25-羟维生素D[25-(OH)D]、腰椎L1-4和股骨颈骨密度、骨吸收抑制剂使用率及合并高血压、糖尿病、心脏病发生率比较,差异无统计学意义(P0.05)。高龄组患者药物不良反应发生率低于老年组,差异有统计学意义(P0.05)。是否发生药物不良反应患者的年龄、骨吸收抑制剂使用率比较,差异有统计学意义(P0.05);控制骨吸收抑制剂使用情况因素后,高龄与药物不良反应发生呈负相关(P0.05)。结论唑来膦酸注射液治疗75岁及以上高龄老年性骨质疏松患者的急性期不良反应发生率低于75岁以下患者,高龄与不良反应发生呈负相关。
[Abstract]:Objective to investigate the incidence of adverse drug reactions in the treatment of senile osteoporosis with zoledronic acid injection, and to explore the correlation between the elderly and adverse drug reactions. Methods from March 2011 to July 2016, 45 patients with senile osteoporosis who were admitted to Yangzhou first people's Hospital from March 2011 to July 2016 were divided into two groups according to their age: the aged group (60 ~ 74 years old) and the elderly group (75 ~ 88 years old). The baseline data and adverse drug reactions were collected and compared between the two groups, and the correlation between the elderly and adverse drug reactions was investigated by partial correlation analysis. Results BMI, osteocalcin, calcium, phosphorus, alkaline phosphatase, parathyroid hormone 25-(OH)D, lumbar L1-4 and femoral neck bone mineral density, bone resorption inhibitor utilization rate and complicated hypertension, diabetes mellitus were observed in both groups. There was no significant difference in the incidence of heart disease (P 0.05). The incidence of adverse drug reactions in the elderly group was significantly lower than that in the elderly group (P 0.05). There were significant differences in the age and the utilization rate of bone resorption inhibitors in patients with adverse drug reactions, and there was a negative correlation between old age and adverse drug reactions after controlling the use of bone resorption inhibitors. Conclusion the incidence of acute adverse reactions in senile osteoporosis patients aged 75 years or older treated with zoledronic acid injection is lower than that in patients under 75 years old.
【作者单位】：江苏省扬州市第一人民医院内分泌科;
【分类号】：R580

【相似文献】